Dare Bioscience (DARE) Competitors $2.11 +0.02 (+0.96%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.12 +0.01 (+0.47%) As of 10/24/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. LFVN, SLGL, EXOZ, MGX, MGNX, HLVX, ATYR, SCLX, CNTB, and VIRIShould you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include Lifevantage (LFVN), Sol-Gel Technologies (SLGL), eXoZymes (EXOZ), Metagenomi (MGX), MacroGenics (MGNX), HilleVax (HLVX), aTyr Pharma (ATYR), Scilex (SCLX), Connect Biopharma (CNTB), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry. Dare Bioscience vs. Its Competitors Lifevantage Sol-Gel Technologies eXoZymes Metagenomi MacroGenics HilleVax aTyr Pharma Scilex Connect Biopharma Virios Therapeutics Lifevantage (NASDAQ:LFVN) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Does the media prefer LFVN or DARE? In the previous week, Lifevantage and Lifevantage both had 2 articles in the media. Lifevantage's average media sentiment score of 0.95 equaled Dare Bioscience'saverage media sentiment score. Company Overall Sentiment Lifevantage Positive Dare Bioscience Positive Which has stronger valuation & earnings, LFVN or DARE? Lifevantage has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$228.53M0.48$9.81M$0.7411.72Dare Bioscience-$17.70K-1,606.85-$4.05M-$2.14-0.99 Do analysts prefer LFVN or DARE? Lifevantage currently has a consensus price target of $30.50, indicating a potential upside of 251.79%. Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 373.93%. Given Dare Bioscience's higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders believe in LFVN or DARE? 35.3% of Lifevantage shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Comparatively, 4.8% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is LFVN or DARE more profitable? Lifevantage has a net margin of 4.29% compared to Dare Bioscience's net margin of 0.00%. Lifevantage's return on equity of 33.75% beat Dare Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.29% 33.75% 15.26% Dare Bioscience N/A N/A -103.70% Which has more risk and volatility, LFVN or DARE? Lifevantage has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. SummaryLifevantage beats Dare Bioscience on 11 of the 13 factors compared between the two stocks. Get Dare Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDare BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.17M$3.42B$6.24B$10.69BDividend YieldN/A2.27%5.72%4.82%P/E Ratio-0.9927.6331.3430.83Price / Sales-1,606.85461.42562.89174.99Price / CashN/A46.1437.0861.44Price / Book-3.0610.4012.056.61Net Income-$4.05M-$52.83M$3.33B$277.10M7 Day Performance3.94%2.10%1.93%2.56%1 Month Performance1.44%12.33%7.77%3.77%1 Year Performance-42.19%14.14%56.40%33.01% Dare Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDare Bioscience2.3367 of 5 stars$2.11+1.0%$10.00+373.9%-39.7%$28.17M-$17.70K-0.9930Analyst ForecastLFVNLifevantage4.2843 of 5 stars$9.06+1.1%$30.50+236.6%-33.2%$113.71M$228.53M12.24260Analyst ForecastSLGLSol-Gel Technologies1.4728 of 5 stars$39.95+2.5%N/A+526.0%$108.62M$11.54M-32.4850News CoveragePositive NewsAnalyst ForecastEXOZeXoZymes0.3107 of 5 stars$12.99+0.3%N/AN/A$108.61M$70K0.0029News CoverageAnalyst ForecastMGXMetagenomi2.9907 of 5 stars$2.85-0.3%$10.00+250.9%+50.5%$107.35M$52.29M-1.21236News CoverageAnalyst UpgradeMGNXMacroGenics4.5253 of 5 stars$1.64-3.0%$3.60+119.5%-48.9%$106.82M$149.96M-2.88430Positive NewsAnalyst ForecastHLVXHilleVaxN/A$2.09flat$2.00-4.3%N/A$104.79MN/A-1.4620ATYRaTyr Pharma3.06 of 5 stars$0.97-8.9%$23.25+2,307.3%-70.2%$103.87MN/A-1.2153Trending NewsAnalyst ForecastSCLXScilex2.587 of 5 stars$14.74-1.3%$455.00+2,986.8%-47.8%$103.85M$56.59M-0.5180Positive NewsAnalyst ForecastGap UpCNTBConnect Biopharma3.0492 of 5 stars$1.82-2.2%$7.00+284.6%+39.3%$103.64M$26.03M0.00110News CoverageAnalyst ForecastVIRIVirios TherapeuticsN/A$5.37-4.1%N/A+36.1%$103.42MN/A-19.895 Related Companies and Tools Related Companies Lifevantage Alternatives Sol-Gel Technologies Alternatives eXoZymes Alternatives Metagenomi Alternatives MacroGenics Alternatives HilleVax Alternatives aTyr Pharma Alternatives Scilex Alternatives Connect Biopharma Alternatives Virios Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DARE Stock Alerts